{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T19:51:15Z","timestamp":1782849075434,"version":"3.54.5"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s00059-025-05327-9","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T13:29:00Z","timestamp":1756128540000},"page":"395-404","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Diagnose und Therapie der Herzinsuffizienz mit erhaltener Ejektionsfraktion","Diagnosis and treatment of heart failure with preserved ejection fraction"],"prefix":"10.1007","volume":"50","author":[{"given":"Samira","family":"Soltani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Bauersachs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,25]]},"reference":[{"key":"5327_CR1","unstructured":"https:\/\/epaper.herzstiftung.de\/epaper\/ausgabe.pdf. Zugegriffen: 5. Okt. 2024"},{"key":"5327_CR2","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"ehab368","author":"TA McDonagh","year":"2021","unstructured":"McDonagh\u00a0TA, Metra\u00a0M, Adamo\u00a0M et\u00a0al (2021) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart\u00a0J ehab368:3599\u20133726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368","journal-title":"Eur Heart J"},{"key":"5327_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jcmg.2017.08.007","volume":"11","author":"RS Vasan","year":"2018","unstructured":"Vasan\u00a0RS, Xanthakis\u00a0V, Lyass\u00a0A et\u00a0al (2018) Epidemiology of Left Ventricular Systolic Dysfunction and Heart Failure in the Framingham Study An Echocardiographic Study Over 3 Decades. JACC Cardiovasc Imaging 11:1\u201311. https:\/\/doi.org\/10.1016\/j.jcmg.2017.08.007","journal-title":"JACC Cardiovasc Imaging"},{"key":"5327_CR4","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s00392-024-02396-4","volume":"113","author":"S von Haehling","year":"2024","unstructured":"von Haehling\u00a0S, Assmus\u00a0B, Bekfani\u00a0T et\u00a0al (2024) Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment. Clin Res Cardiol 113:1287\u20131305. https:\/\/doi.org\/10.1007\/s00392-024-02396-4","journal-title":"Clin Res Cardiol"},{"key":"5327_CR5","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1002\/ejhf.2894","volume":"25","author":"SD Anker","year":"2023","unstructured":"Anker\u00a0SD, Usman\u00a0MS, Anker\u00a0MS et\u00a0al (2023) Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A\u00a0scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension. Eur J Hear Fail 25:936\u2013955. https:\/\/doi.org\/10.1002\/ejhf.2894","journal-title":"Eur J Hear Fail"},{"key":"5327_CR6","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1161\/circulationaha.118.034646","volume":"138","author":"YNV Reddy","year":"2018","unstructured":"Reddy\u00a0YNV, Carter\u00a0RE, Obokata\u00a0M et\u00a0al (2018) A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction. Circulation 138:861\u2013870. https:\/\/doi.org\/10.1161\/circulationaha.118.034646","journal-title":"Circulation"},{"key":"5327_CR7","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/ejhf.1741","volume":"22","author":"B Pieske","year":"2020","unstructured":"Pieske\u00a0B, Tsch\u00f6pe\u00a0C, de Boer\u00a0RA et\u00a0al (2020) How to diagnose heart failure with preserved ejection fraction: the HFA\u2013PEFF diagnostic algorithm: a\u00a0consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail 22:391\u2013412. https:\/\/doi.org\/10.1002\/ejhf.1741","journal-title":"Eur J Heart Fail"},{"key":"5327_CR8","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1002\/ejhf.1461","volume":"21","author":"PM Seferovi\u0107","year":"2019","unstructured":"Seferovi\u0107\u00a0PM, Polovina\u00a0M, Bauersachs\u00a0J et\u00a0al (2019) Heart failure in cardiomyopathies: a\u00a0position paper from the Heart Failure Association of the European Society of Cardiology. Eur J Hear Fail 21:553\u2013576. https:\/\/doi.org\/10.1002\/ejhf.1461","journal-title":"Eur J Hear Fail"},{"key":"5327_CR9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12916-021-02219-7","volume":"20","author":"J Liu","year":"2022","unstructured":"Liu\u00a0J, Wang\u00a0D, Ruan\u00a0J et\u00a0al (2022) Identification of heart failure with preserved ejection fraction helps risk stratification for hypertrophic cardiomyopathy. BMC Med 20:21. https:\/\/doi.org\/10.1186\/s12916-021-02219-7","journal-title":"BMC Med"},{"key":"5327_CR10","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.15420\/cfr.2019.16","volume":"6","author":"SH Klaassen","year":"2020","unstructured":"Klaassen\u00a0SH, van Veldhuisen\u00a0DJ, Nienhuis\u00a0HL et\u00a0al (2020) Cardiac Transthyretin-derived Amyloidosis: An Emerging Target in Heart Failure with Preserved Ejection Fraction? Card Fail Rev 6:e21. https:\/\/doi.org\/10.15420\/cfr.2019.16","journal-title":"Card Fail Rev"},{"key":"5327_CR11","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1093\/eurheartj\/ehv318","volume":"36","author":"Y Adler","year":"2015","unstructured":"Adler\u00a0Y, Charron\u00a0P, Imazio\u00a0M et\u00a0al (2015) 2015 ESC Guidelines for the diagnosis and management of pericardial diseases. Eur Heart\u00a0J 36:2921\u20132964. https:\/\/doi.org\/10.1093\/eurheartj\/ehv318","journal-title":"Eur Heart J"},{"key":"5327_CR12","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/s0140-6736(03)14285-7","volume":"362","author":"S Yusuf","year":"2003","unstructured":"Yusuf\u00a0S, Pfeffer\u00a0MA, Swedberg\u00a0K et\u00a0al (2003) Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362:777\u2013781. https:\/\/doi.org\/10.1016\/s0140-6736(03)14285-7","journal-title":"Lancet"},{"key":"5327_CR13","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1056\/nejmoa0805450","volume":"359","author":"BM Massie","year":"2008","unstructured":"Massie\u00a0BM, Carson\u00a0PE, McMurray\u00a0JJ et\u00a0al (2008) Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction. N\u00a0Engl J Med 359:2456\u20132467. https:\/\/doi.org\/10.1056\/nejmoa0805450","journal-title":"N Engl J Med"},{"key":"5327_CR14","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1161\/circheartfailure.111.964221","volume":"5","author":"TS Rector","year":"2012","unstructured":"Rector\u00a0TS, Carson\u00a0PE, Anand\u00a0IS et\u00a0al (2012) Assessment of Long-Term Effects of Irbesartan on Heart Failure With Preserved Ejection Fraction as Measured by the Minnesota Living With Heart Failure Questionnaire in the Irbesartan in Heart Failure With Preserved Systolic Function (I-PRESERVE) Trial. Circ Heart Fail 5:217\u2013225. https:\/\/doi.org\/10.1161\/circheartfailure.111.964221","journal-title":"Circ Heart Fail"},{"key":"5327_CR15","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1093\/eurheartj\/ehl250","volume":"27","author":"JGF Cleland","year":"2006","unstructured":"Cleland\u00a0JGF, Tendera\u00a0M, Adamus\u00a0J et\u00a0al (2006) The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart\u00a0J 27:2338\u20132345. https:\/\/doi.org\/10.1093\/eurheartj\/ehl250","journal-title":"Eur Heart J"},{"key":"5327_CR16","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/nejmoa1908655","volume":"381","author":"SD Solomon","year":"2019","unstructured":"Solomon\u00a0SD, McMurray\u00a0JJV, Anand\u00a0IS et\u00a0al (2019) Angiotensin\u2013Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N\u00a0Engl J Med 381:1609\u20131620. https:\/\/doi.org\/10.1056\/nejmoa1908655","journal-title":"N Engl J Med"},{"key":"5327_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jacc.2023.04.019","volume":"82","author":"RJ Mentz","year":"2023","unstructured":"Mentz\u00a0RJ, Ward\u00a0JH, Hernandez\u00a0AF et\u00a0al (2023) Angiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure. J\u00a0Am Coll Cardiol 82:1\u201312. https:\/\/doi.org\/10.1016\/j.jacc.2023.04.019","journal-title":"J Am Coll Cardiol"},{"key":"5327_CR18","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/nejmoa1313731","volume":"370","author":"B Pitt","year":"2014","unstructured":"Pitt\u00a0B, Pfeffer\u00a0MA, Assmann\u00a0SF et\u00a0al (2014) Spironolactone for Heart Failure with Preserved Ejection Fraction. N\u00a0Engl J Med 370:1383\u20131392. https:\/\/doi.org\/10.1056\/nejmoa1313731","journal-title":"N Engl J Med"},{"key":"5327_CR19","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/nejmoa2407107","volume":"391","author":"SD Solomon","year":"2024","unstructured":"Solomon\u00a0SD, McMurray\u00a0JJV, Vaduganathan\u00a0M et\u00a0al (2024) Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N\u00a0Engl J Med 391:1475\u20131485. https:\/\/doi.org\/10.1056\/nejmoa2407107","journal-title":"N Engl J Med"},{"key":"5327_CR20","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.124.072011","author":"KF Docherty","year":"2024","unstructured":"Docherty\u00a0KF, Henderson\u00a0AD, Jhund\u00a0PS et\u00a0al (2024) Efficacy and Safety of Finerenone Across the Ejection Fraction Spectrum in Heart Failure with Mildly Reduced and Preserved Ejection Fraction: a\u00a0Prespecified Analysis of The FINEARTS-HF Trial. Circulation. https:\/\/doi.org\/10.1161\/circulationaha.124.072011","journal-title":"Circulation"},{"key":"5327_CR21","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1001\/jamacardio.2023.5500","volume":"9","author":"P Palau","year":"2024","unstructured":"Palau\u00a0P, de la Espriella\u00a0R, Seller\u00a0J et\u00a0al (2024) \u03b2\u2011Blocker Withdrawal and Functional Capacity Improvement in Patients With Heart Failure With Preserved Ejection Fraction. JAMA Cardiol 9:392\u2013396. https:\/\/doi.org\/10.1001\/jamacardio.2023.5500","journal-title":"JAMA Cardiol"},{"key":"5327_CR22","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s10741-014-9453-8","volume":"20","author":"C Bavishi","year":"2015","unstructured":"Bavishi\u00a0C, Chatterjee\u00a0S, Ather\u00a0S et\u00a0al (2015) Beta-blockers in heart failure with preserved ejection fraction: a\u00a0meta-analysis. Hear Fail Rev 20:193\u2013201. https:\/\/doi.org\/10.1007\/s10741-014-9453-8","journal-title":"Hear Fail Rev"},{"key":"5327_CR23","doi-asserted-by":"publisher","first-page":"e007180","DOI":"10.1161\/circheartfailure.120.007180","volume":"13","author":"EL Fu","year":"2020","unstructured":"Fu\u00a0EL, Uijl\u00a0A, Dekker\u00a0FW et\u00a0al (2020) Association Between \u03b2\u2011Blocker Use and Mortality\/Morbidity in Patients With Heart Failure With Reduced, Midrange, and Preserved Ejection Fraction and Advanced Chronic Kidney Disease. Circ Heart Fail 13:e7180. https:\/\/doi.org\/10.1161\/circheartfailure.120.007180","journal-title":"Circ Heart Fail"},{"key":"5327_CR24","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.2014.15241","volume":"312","author":"LH Lund","year":"2014","unstructured":"Lund\u00a0LH, Benson\u00a0L, Dahlstr\u00f6m\u00a0U et\u00a0al (2014) Association Between Use of \u03b2\u2011Blockers and Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. JAMA 312:2008\u20132018. https:\/\/doi.org\/10.1001\/jama.2014.15241","journal-title":"JAMA"},{"key":"5327_CR25","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/nejmoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker\u00a0SD, Butler\u00a0J, Filippatos\u00a0G et\u00a0al (2021) Empagliflozin in Heart Failure with a\u00a0Preserved Ejection Fraction. N\u00a0Engl J Med 385:1451\u20131461. https:\/\/doi.org\/10.1056\/nejmoa2107038","journal-title":"N Engl J Med"},{"key":"5327_CR26","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","volume":"44","author":"TA McDonagh","year":"2023","unstructured":"McDonagh\u00a0TA, Metra\u00a0M, Adamo\u00a0M et\u00a0al (2023) 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart\u00a0J 44:3627\u20133639. https:\/\/doi.org\/10.1093\/eurheartj\/ehad195","journal-title":"Eur Heart J"},{"key":"5327_CR27","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1056\/nejmcp2305181","volume":"392","author":"A Cannata","year":"2025","unstructured":"Cannata\u00a0A, McDonagh\u00a0TA (2025) Heart Failure with Preserved Ejection Fraction. N\u00a0Engl J Med 392:173\u2013184. https:\/\/doi.org\/10.1056\/nejmcp2305181","journal-title":"N Engl J Med"},{"key":"5327_CR28","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1056\/nejmoa2313917","volume":"390","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod\u00a0MN, Petrie\u00a0MC, Borlaug\u00a0BA et\u00a0al (2024) Semaglutide in Patients with Obesity-Related Heart Failure and Type\u00a02 Diabetes. N\u00a0Engl J Med 390:1394\u20131407. https:\/\/doi.org\/10.1056\/nejmoa2313917","journal-title":"N Engl J Med"},{"key":"5327_CR29","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/nejmoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod\u00a0MN, Abildstr\u00f8m\u00a0SZ, Borlaug\u00a0BA et\u00a0al (2023) Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N\u00a0Engl J Med 389:1069\u20131084. https:\/\/doi.org\/10.1056\/nejmoa2306963","journal-title":"N Engl J Med"},{"issue":"392","key":"5327_CR30","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/nejmoa2410027","volume":"2025","author":"M Packer","year":"2024","unstructured":"Packer\u00a0M, Zile\u00a0MR, Kramer\u00a0CM et\u00a0al (2024) Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N\u00a0Engl J Med 2025(392):427\u2013437. https:\/\/doi.org\/10.1056\/nejmoa2410027","journal-title":"N Engl J Med"},{"key":"5327_CR31","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.1093\/eurheartj\/ehae479","volume":"45","author":"S von Haehling","year":"2024","unstructured":"von Haehling\u00a0S, Doehner\u00a0W, Evertz\u00a0R et\u00a0al (2024) Ferric carboxymaltose and exercise capacity in heart failure with preserved ejection fraction and iron deficiency: the FAIR-HFpEF trial. Eur Hear\u00a0J 45:3789\u20133800. https:\/\/doi.org\/10.1093\/eurheartj\/ehae479","journal-title":"Eur Hear J"},{"key":"5327_CR32","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jacc.2024.04.047","volume":"84","author":"RT Hahn","year":"2024","unstructured":"Hahn\u00a0RT, Lindenfeld\u00a0J, B\u00f6hm\u00a0M et\u00a0al (2024) Tricuspid Regurgitation in Patients With Heart Failure and Preserved Ejection Fraction JACC State-of-the-Art Review. J\u00a0Am Coll Cardiol 84:195\u2013212. https:\/\/doi.org\/10.1016\/j.jacc.2024.04.047","journal-title":"J Am Coll Cardiol"},{"key":"5327_CR33","doi-asserted-by":"publisher","first-page":"5010","DOI":"10.1002\/ehf2.13561","volume":"8","author":"M Gr\u00f6ger","year":"2021","unstructured":"Gr\u00f6ger\u00a0M, Scheffler\u00a0JK, Sch\u00f6sser\u00a0F et\u00a0al (2021) Percutaneous edge-to-edge mitral valve repair for mitral regurgitation improves heart failure symptoms in heart failure with preserved ejection fraction patients. Esc Hear Fail 8:5010\u20135021. https:\/\/doi.org\/10.1002\/ehf2.13561","journal-title":"Esc Hear Fail"},{"key":"5327_CR34","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1056\/nejmoa2300525","volume":"388","author":"P Sorajja","year":"2023","unstructured":"Sorajja\u00a0P, Whisenant\u00a0B, Hamid\u00a0N et\u00a0al (2023) Transcatheter Repair for Patients with Tricuspid Regurgitation. N\u00a0Engl J Med 388:1833\u20131842. https:\/\/doi.org\/10.1056\/nejmoa2300525","journal-title":"N Engl J Med"},{"key":"5327_CR35","doi-asserted-by":"publisher","first-page":"4539","DOI":"10.1093\/eurheartj\/ehae544","volume":"45","author":"KM Talha","year":"2024","unstructured":"Talha\u00a0KM, Metra\u00a0M, Butler\u00a0J (2024) Heart failure with preserved ejection fraction: underdiagnosed and undertreated in patients with tricuspid regurgitation. Eur Hear\u00a0J 45:4539\u20134541. https:\/\/doi.org\/10.1093\/eurheartj\/ehae544","journal-title":"Eur Hear J"}],"container-title":["Herz"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-025-05327-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00059-025-05327-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-025-05327-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T08:50:06Z","timestamp":1759395006000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00059-025-05327-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,25]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["5327"],"URL":"https:\/\/doi.org\/10.1007\/s00059-025-05327-9","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"value":"0340-9937","type":"print"},{"value":"1615-6692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,25]]},"assertion":[{"value":"9 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"J.\u00a0Bauersachs hat von Novartis, Abbott, Bayer, Pfizer, Boehringer Ingelheim, AstraZeneca, Cardior, CVRx, BMS, Amgen, Edwards, Roche, Zoll Honorare f\u00fcr Vortrags- und Beratert\u00e4tigkeiten sowie Forschungsunterst\u00fctzung f\u00fcr die Institution von Zoll, CVRx, Abiomed, Norgine, Roche erhalten. S. Soltani hat Honorare f\u00fcr Vortr\u00e4ge von AstraZeneca und KelCon erhalten. S.\u00a0Soltani und J.\u00a0Bauersachs geben an, dass kein Interessenkonflikt im Zusammenhang mit diesem Artikel besteht.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}